Johan W. Smit
Research Subjects
Research Interests
Johan W. Smit has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
Bernhard Mangold
2 shared publicationsDavid Upmalis
2 shared publicationsCharles Oh
Johnson & Johnson Pharmaceutical Research & Development, L.L.C., Raritan, New Jersey
1 shared publication- Eef Hoeben
Janssen Research & Development BVBA, Beerse, Belgium
1 shared publication Jens Rengelshausen
Global Development, Grünenthal GmbH, Aachen, Germany
1 shared publication- Klaus Schaffler
HPR (Human Pharmacodynamic Research) Dr. Schaffler GmbH, Munich, Germany
1 shared publication
Latest Publications
- 1 August 2012
- Published by Wolters Kluwer Health in Pain
- Vol. 153 (8) , 1648-1656
Dose-response relationship after single oral dose administrations of morphine and oxycodone using laser-evoked potentials on UVB- and capsaicin-irritated skin in healthy male subjects
TOC summary The analgesic/antihyperalgesic efficacy and dose-response relationship of 2 opioids was demonstrated in a human experimental algesimetric model using laser stimuli applied to sensitized skin. The aim of the study was to evaluate the analgesic/antihyperalgesic efficacy and to establish the dose-response relationship of morphine immediate release (IR) and oxycodone IR in a human experimental algesimetric model. Calculated effect ratios for peak-to-peak (PtP) amplitudes of laser-evoked potentials (LEPs) and visual analog scales (VAS) postlaser pain on UVB-irradiated skin (main target variables) were 1.68 and 1.18 respectively for oxycodone 10 mg/morphine 20 mg, 3.00 and 1.63 respectively for oxycodone 15 mg/morphine 30 mg, and 1.12 and 1.25 respectively for oxycodone 20 mg/morphine 40 mg. The effect on the laser-PtP amplitude of morphine at the highest dose (40 mg) and of oxycodone at all doses (10, 15, 20 mg) was considered to be clinically relevant based on a difference from placebo of ≥2.5 μV. For both compounds, a statistically significant linear trend was observed between dose groups in at least 1 of the 2 main target variables (adjusted P value for both end points <.001 at all doses). Hyperalgesia developed over time vs baseline due to acute exposure to UVB irradiation and to topical/occlusive 1% capsaicin solution. For both compounds, the principal onset of analgesic/antihyperalgesic drug effects was around 0.5 hours with an average peak at about 1 to 2 hours and the effect lasting for more than 3 hours (morphine 20 and 30 mg) or 6 hours (morphine 40 mg and oxycodone all doses). In conclusion, the study demonstrated a solid outcome of a mixed objective/subjective human experimental algesimetric model to approach dose-response relationships and analgesic/antihyperalgesic effects of 2 opioids.
- 1 August 2012
- Published by Wolters Kluwer Health in Pain
- Vol. 153 (8) , 1648-1656
Dose-response relationship after single oral dose administrations of morphine and oxycodone using laser-evoked potentials on UVB- and capsaicin-irritated skin in healthy male subjects
TOC summary The analgesic/antihyperalgesic efficacy and dose-response relationship of 2 opioids was demonstrated in a human experimental algesimetric model using laser stimuli applied to sensitized skin. The aim of the study was to evaluate the analgesic/antihyperalgesic efficacy and to establish the dose-response relationship of morphine immediate release (IR) and oxycodone IR in a human experimental algesimetric model. Calculated effect ratios for peak-to-peak (PtP) amplitudes of laser-evoked potentials (LEPs) and visual analog scales (VAS) postlaser pain on UVB-irradiated skin (main target variables) were 1.68 and 1.18 respectively for oxycodone 10 mg/morphine 20 mg, 3.00 and 1.63 respectively for oxycodone 15 mg/morphine 30 mg, and 1.12 and 1.25 respectively for oxycodone 20 mg/morphine 40 mg. The effect on the laser-PtP amplitude of morphine at the highest dose (40 mg) and of oxycodone at all doses (10, 15, 20 mg) was considered to be clinically relevant based on a difference from placebo of ≥2.5 μV. For both compounds, a statistically significant linear trend was observed between dose groups in at least 1 of the 2 main target variables (adjusted P value for both end points <.001 at all doses). Hyperalgesia developed over time vs baseline due to acute exposure to UVB irradiation and to topical/occlusive 1% capsaicin solution. For both compounds, the principal onset of analgesic/antihyperalgesic drug effects was around 0.5 hours with an average peak at about 1 to 2 hours and the effect lasting for more than 3 hours (morphine 20 and 30 mg) or 6 hours (morphine 40 mg and oxycodone all doses). In conclusion, the study demonstrated a solid outcome of a mixed objective/subjective human experimental algesimetric model to approach dose-response relationships and analgesic/antihyperalgesic effects of 2 opioids.
- 6 January 2010
- Published by Wiley in Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
- Vol. 30 (1) , 25-34
Effects of Acetaminophen, Naproxen, and Acetylsalicylic Acid on Tapentadol Pharmacokinetics: Results of Two Randomized, Open‐Label, Crossover, Drug‐Drug Interaction Studies
Study Objective. To evaluate the effects of acetaminophen, naproxen, and acetylsalicylic acid on the pharmacokinetics of the centrally acting analgesic tapentadol in healthy subjects.Design. Two randomized, open‐label, crossover, drug‐drug interaction studies.Setting. Clinical research facilities in the United States and Belgium.Participants. Twenty‐four healthy adults (2‐way crossover study) and 38 healthy adults (3‐way crossover study).Interventions. In both studies, tapentadol immediate release (IR) 80 mg was administered as a single oral dose alone. In the 2‐way crossover study, tapentadol IR was also given with the fifth of seven doses of acetaminophen 1000 mg; in the 3‐way crossover study, tapentadol IR was also given with the third of four doses of naproxen 500 mg and the second of two doses of acetylsalicylic acid 325 mg. All treatments were separated by a washout period of 7–14 days.Measurements and Main Results. Overall, mean serum concentrations were similar after administration of tapentadol IR alone and after coadministration with acetaminophen or acetylsalicylic acid, and the 90% confidence intervals (CIs) for the ratios of the mean area under the serum concentration‐time curve (AUC) from time zero to time of the last measurable concentration (AUC0‐t) and from time zero extrapolated to infinity (AUC0‐$iF) and the maximum serum concentration (Cmax) of the combined treatments to those parameters of tapentadol alone were well within 80–125%, representing the accepted range for bioequivalence. Coadministration of naproxen did not significantly alter the Cmax of tapentadol, although a slightly higher serum tapentadol exposure relative to tapentadol alone was observed. Coadministration of naproxen resulted in a mean increase of 17% in AUCs, and the upper limits of the 90% CIs for the ratios of the mean AUC0‐t and AUCo‐$iF were slightly outside the upper limit of bioequivalence range of 80–125% (126.47% AUC0‐t and 126.14% AUC0‐$iF).Conclusion. No clinically relevant changes were noted in the serum concentrations of tapentadol, and accordingly, no dosage adjustments with respect to the investigated pharmacokinetic mechanism of interaction are warranted for the administration of tapentadol given concomitantly with acetaminophen, naproxen, or acetylsalicylic acid.
- 6 January 2010
- Published by Wiley in Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
- Vol. 30 (1) , 25-34
Effects of Acetaminophen, Naproxen, and Acetylsalicylic Acid on Tapentadol Pharmacokinetics: Results of Two Randomized, Open‐Label, Crossover, Drug‐Drug Interaction Studies
Study Objective. To evaluate the effects of acetaminophen, naproxen, and acetylsalicylic acid on the pharmacokinetics of the centrally acting analgesic tapentadol in healthy subjects.Design. Two randomized, open‐label, crossover, drug‐drug interaction studies.Setting. Clinical research facilities in the United States and Belgium.Participants. Twenty‐four healthy adults (2‐way crossover study) and 38 healthy adults (3‐way crossover study).Interventions. In both studies, tapentadol immediate release (IR) 80 mg was administered as a single oral dose alone. In the 2‐way crossover study, tapentadol IR was also given with the fifth of seven doses of acetaminophen 1000 mg; in the 3‐way crossover study, tapentadol IR was also given with the third of four doses of naproxen 500 mg and the second of two doses of acetylsalicylic acid 325 mg. All treatments were separated by a washout period of 7–14 days.Measurements and Main Results. Overall, mean serum concentrations were similar after administration of tapentadol IR alone and after coadministration with acetaminophen or acetylsalicylic acid, and the 90% confidence intervals (CIs) for the ratios of the mean area under the serum concentration‐time curve (AUC) from time zero to time of the last measurable concentration (AUC0‐t) and from time zero extrapolated to infinity (AUC0‐$iF) and the maximum serum concentration (Cmax) of the combined treatments to those parameters of tapentadol alone were well within 80–125%, representing the accepted range for bioequivalence. Coadministration of naproxen did not significantly alter the Cmax of tapentadol, although a slightly higher serum tapentadol exposure relative to tapentadol alone was observed. Coadministration of naproxen resulted in a mean increase of 17% in AUCs, and the upper limits of the 90% CIs for the ratios of the mean AUC0‐t and AUCo‐$iF were slightly outside the upper limit of bioequivalence range of 80–125% (126.47% AUC0‐t and 126.14% AUC0‐$iF).Conclusion. No clinically relevant changes were noted in the serum concentrations of tapentadol, and accordingly, no dosage adjustments with respect to the investigated pharmacokinetic mechanism of interaction are warranted for the administration of tapentadol given concomitantly with acetaminophen, naproxen, or acetylsalicylic acid.